As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Type of study:
Phase I study
Patients receive oral ABT-888 twice daily on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV and vinorelbine IV on days 1 and 8. Treatment repeats every 21 days for 6- 10 courses in the absence of disease progression or unacceptable toxicity. Treatment with ABT-888 alone may continue in the absence of disease progression or unacceptable toxicity.
Fred Hutchinson Cancer Research Center/University of Washington Cancer
Seattle, Washington, 98109
Contact: Phase I Program 206-288-7551 email@example.com
Principal Investigator: John Thompson